MHRA Grants Marketing Authorisation for Arrowhead’s REDEMPLO

Arrowhead Pharmaceuticals says the UK Medicines and Healthcare products Regulatory Agency granted marketing authorisation for REDEMPLO for adults with familial chylomicronaemia syndrome (FCS).